Pharmaceutical industry financial penalties U.S. 1991-2017

This statistic represents pharmaceutical industry penalties from settlements between US state and federal governments from 1991 to 2017. In 2009, penalties for the pharmaceutical industry in the United States came to some 4.4 billion U.S. dollars in total.

Pharmaceutical industry financial penalties in the United States from 1991 to 2017 (in million U.S. dollars)*

Characteristic	Penalties in million U.S. dollars
2017	1,304
2016**	1,592
2015	2,208
2014	642
2013	3,500
2012	6,348
2011	2,338
2010	4,339
2009	4,412
2008	1,429
2007	1,441
2006	3,976
2005	1,067
2004	999
2003	967
2002	549
2001	889
2000	489
1999	100
1998	3
1997	4
1996	7
1995	10
1994	0
1993	1
1992	22
1991	10

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

March 2018

More information

Region

United States

Survey time period

1991 to 2017

Supplementary notes

* From settlements between the federal and state governments and pharmaceutical manufacturers.

An additional multi-state settlement, reached in 2016 with Teva’s Cephalon subsidiary for monopoly practices, involved a $125 million civil monetary fine. However, the entirety of this fine was paid from a previous (2015) $1.2 billion civil settlement payment by Teva’s Cephalon subsidiary to the federal government. Because this $1.2 billion federal financial penalty already was included in our database, we did not include the $125 million multi-state settlement payment so as not to count Teva’s settlement payment twice.

Citation formats